HIP
TARO

Hatteras Investment Partners’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Hatteras Investment Partners’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-7,680
Closed -$1.19M – 108
2015
Q4 		$1.19M Buy
+7,680
New +$1.12M 1.55% 14

Other funds holding TARO

Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $292M AUM 75.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GCM
Greywolf Capital Management Purchase, New York $67.3M AUM 100.05% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
FCH
Freestone Capital Holdings Seattle, Washington $3.86B AUM 26.3% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Hatteras Investment Partners's TARO Position: Q1 2016 in Review

Hatteras Investment Partners sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q1 2016, closing a stake of 7,680 shares — an estimated $1.19M sold.

Hatteras Investment Partners first reported a position in TARO in Q4 2015 and held it in 1 quarter. The position peaked at $1.19M in Q4 2015. 167 funds tracked by Wall St. Rank hold TARO as of Q1 2016.

  • Hatteras Investment Partners reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q1 2016 after selling out during the quarter.
  • Hatteras Investment Partners sold 7,680 Taro Pharmaceutical Industries Ltd. shares in Q1 2016, an estimated $1.19M.
  • Hatteras Investment Partners first reported a position in Taro Pharmaceutical Industries Ltd. in Q4 2015 and held it in 1 quarter.
  • Hatteras Investment Partners's Taro Pharmaceutical Industries Ltd. position peaked at $1.19M in Q4 2015.
  • 167 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q1 2016.

Based on Hatteras Investment Partners's 13F filing for Q1 2016, filed 16 May 2016.